Zuellig Pharma Korea grapples with tougher domestic market

Published: 2003-03-25 07:00:00

Updated: 2003-03-25 07:00:00

Following revelation of Zuellig Pharma Korea's two-year consecutive deficits, there are lingering concerns about its successful presence (or viability) in the domestic market, as its financial index have successfully been deteriorating albeit increasing sales volume per year. It is presumed that ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK